Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)-Reference-Cited by-同舟云学术

Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)

Published:2013-07 Issue:7 Volume:6 Page:671-683
ISSN:1936-8798
Container-title:JACC: Cardiovascular Interventions
language:en
Short-container-title:JACC: Cardiovascular Interventions

Author:

Kunadian Vijay,James Stefan K.,Wojdyla Daniel M.,Zorkun Cafer,Wu Jinhui,Storey Robert F.,Steg Ph. Gabriel,Katus Hugo,Emanuelsson Hakan,Horrow Jay,Maya Juan,Wallentin Lars,Harrington Robert A.,Gibson C. Michael

Funder

AstraZeneca

Eli Lilly

Merck & Co., Inc.

Bristol-Myers Squibb

The Medicines Company

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference29 articles.

1. Ticagrelor versus clopidogrel in patients with acute coronary syndromes;Wallentin;N Engl J Med,2009

2. Efficacy and safety of ticagrelor: A reversible P2Y12receptor antagonist;Anderson;Ann Pharmacother,2010

3. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin;Husted;Eur Heart J,2006

4. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes;Storey;J Am Coll Cardiol,2007

5. Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy;Schneider;J Am Coll Cardiol,2011

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers of Thrombotic Status Predict Spontaneous Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction;Journal of the American College of Cardiology;2023-05

2. Antiplatelet agents for chronic kidney disease;Cochrane Database of Systematic Reviews;2022-02-28

3. Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial;European Heart Journal. Acute Cardiovascular Care;2022-02-25

4. Crushed/chewed administration of potent P2Y12 inhibitors in ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Systematic review and meta-analysis;Platelets;2021-09-02

5. Acute Coronary Syndromes (ACS)—Unravelling Biology to Identify New Therapies—The Microcirculation as a Frontier for New Therapies in ACS;Cells;2021-08-25